Response to EFSA's draft opinion on BPA

CRIS experts delve into the scientific literature and respond to EFSA's draft opinion on the ingredient bisphenol A (BPA).

CRIS responds to the draft opinion published by the European Food Safety Authority (EFSA) on the ingredient bisphenol A (BPA). 


In the 2021 “Re-evaluation of the risks to public health related to the presence of bisphenol A (BPA) in foodstuff”, the EFSA CEP concluded that the “immune system was identified as the most sensitive health outcome category to BPA exposure. Specifically, an increase of Th17… in the development of allergic lung inflammation. (Line 23-25)”. The CEP has attempted to link an increase in Th17 cells due to BPA exposure in rodent studies to epidemiology studies claiming a positive association between BPA exposure and atopic allergic respiratory disorders (e.g., wheezing, rhinitis and asthma). In reviewing the EFSA opinion on BPA we have dissenting opinions that fall into four general categories. We have focused on the key papers cited by the CEP.


Below you will find links to the submitted response to the EFSA and our full response that includes citations.

View the EFSA Draft Opinion on BPA at

View our full response including citations at

View our submitted response to the EFSA at

Response submitted on February 22, 2022, to European Food Safety Authority Food Ingredients and Packaging


Response prepared by

Dr. Norbert Kaminski, Director, Center for Research on Ingredient Safety; Director, Institute for Integrated Toxicology; Professor, Pharmacology and Toxicology, Cell and Molecular Biology Program.

Dr. Joseph Zagorski, Assistant Professor, Center for Research on Ingredient Safety.

Did you find this article useful?